UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2014-03, Vol.32 (7), p.671-677

2014

Volltextzugriff (PDF)

Cellular rewiring in lethal prostate cancer: the architect of drug resistance

Nature reviews. Urology, 2020-05, Vol.17 (5), p.292-307

2020

Volltextzugriff (PDF)

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

Clinical cancer research, 2009-05, Vol.15 (9), p.3172-3176

2009

Volltextzugriff (PDF)

Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy

International journal of radiation oncology, biology, physics, 2014-08, Vol.89 (5), p.1038-1046

2014

Volltextzugriff (PDF)

Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy

Prostate cancer and prostatic diseases, 2020-06, Vol.23 (2), p.295-302

2020

Volltextzugriff (PDF)

Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration

Journal of clinical oncology, 2002-10, Vol.20 (19), p.3972-3982

2002

Volltextzugriff (PDF)

Long‐term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high‐risk prostate cancer

BJU international, 2015-07, Vol.116 (1), p.50-56

2015

Volltextzugriff (PDF)

Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer

Journal of clinical oncology, 2008-05, Vol.26 (13), p.2147-2154

2008

Volltextzugriff (PDF)

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

Clinical cancer research, 2007-03, Vol.13 (6), p.1775-1782

2007

Volltextzugriff (PDF)

Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer

Nanomedicine, 2013-11, Vol.9 (8), p.1124-1134

2013

Volltextzugriff (PDF)

Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer

Journal of clinical oncology, 2005-03, Vol.23 (7), p.1439-1446

2005

Volltextzugriff (PDF)

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data

The lancet oncology, 2007-11, Vol.8 (11), p.994-1000

2007

Volltextzugriff (PDF)

Pattern of Prostate-Specific Antigen (PSA) Failure Dictates the Probability of a Positive Bone Scan in Patients With an Increasing PSA After Radical Prostatectomy

Journal of clinical oncology, 2005-03, Vol.23 (9), p.1962-1968

2005

Volltextzugriff (PDF)

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

Journal of clinical oncology, 2014-04, Vol.32 (11), p.1143-1150

2014

Volltextzugriff (PDF)

Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy

Clinical cancer research, 2005-05, Vol.11 (9), p.3210-3216

2005

Volltextzugriff (PDF)

Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer

Clinical cancer research, 2005-10, Vol.11 (20), p.7454-7461

2005

Volltextzugriff (PDF)

Redefining hormone resistance in prostate cancer

Therapeutic Advances in Medical Oncology, 2010-03, Vol.2 (2), p.107-123

2010

Volltextzugriff (PDF)

Neuroendocrine transformation of prostate adenocarcinoma with corpora cavernosa metastases

Canadian journal of urology, 2022-12, Vol.29 (6), p.11399

2022

Volltextzugriff (PDF)

Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data

World journal of urology, 2023-09, Vol.41 (9), p.2351-2357

2023

Volltextzugriff (PDF)

High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy

Journal of clinical oncology, 2005-11, Vol.23 (32), p.8186-8191

2005

Volltextzugriff (PDF)

A Phase II Trial of Bortezomib and Prednisone for Castration Resistant Metastatic Prostate Cancer

The Journal of urology, 2007-12, Vol.178 (6), p.2378-2384

2007

Volltextzugriff (PDF)

Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study

European urology, 2020-05, Vol.77 (5), p.563-572

2020

Volltextzugriff (PDF)

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone

Cancer, 2007-08, Vol.110 (3), p.556-563

2007

Volltextzugriff (PDF)

Counterpoint-Prostate Cancer Genomic Analysis: Routine or Research Only?

Oncology (Williston Park, N.Y.), 2018-12, Vol.32 (12), p.607, 630-607

2018

Volltextzugriff (PDF)

1 – 25 von 1.095

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.018)
Mit Volltextzugriff
(909)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer

Cellular rewiring in lethal prostate cancer: the architect of drug resistance

Nuclear Pores Promote Lethal Prostate Cancer by Increasing POM121-Driven E2F1, MYC, and AR Nuclear Import

An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men with Castrate-Resistant Prostate Cancer

Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy

Prospective study to define the clinical utility and benefit of Decipher testing in men following prostatectomy

Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration

Long‐term oncological outcomes of a phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localised, high‐risk prostate cancer

Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer

Multi-Institutional Randomized Phase II Trial of the Epothilone B Analog Ixabepilone (BMS-247550) With or Without Estramustine Phosphate in Patients With Progressive Castrate Metastatic Prostate Cancer

Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data

Pattern of Prostate-Specific Antigen (PSA) Failure Dictates the Probability of a Positive Bone Scan in Patients With an Increasing PSA After Radical Prostatectomy

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy

Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer

Redefining hormone resistance in prostate cancer

Neuroendocrine transformation of prostate adenocarcinoma with corpora cavernosa metastases

Racial disparities in new-onset diabetes mellitus in prostate cancer patients on androgen deprivation therapy: a retrospective analysis of TriNetX data

High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy

A Phase II Trial of Bortezomib and Prednisone for Castration Resistant Metastatic Prostate Cancer

Veterans Affairs Cooperative Studies Program Study #553: Chemotherapy After Prostatectomy for High-risk Prostate Carcinoma: A Phase III Randomized Study

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : Randomized phase 2 study of ixabepilone or mitoxantrone and prednisone

Counterpoint-Prostate Cancer Genomic Analysis: Routine or Research Only?

Suchergebnisse filtern